Movalis (Meloxicam)

Meloxicam, the active ingredient in Movalis, is a nonsteroidal anti-inflammatory drug presented as a tablet for oral use. It treats inflammation and pain associated with osteoarthritis, rheumatoid arthritis, ankylosing spondylitis and acute musculoskeletal pain in adults.

GNH USA supplies Movalis as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Movalis (meloxicam) is indicated for several inflammatory and musculoskeletal conditions where COX‑2 mediated prostaglandin production contributes to symptoms. - Osteoarthritis: reduces joint pain and improves mobility. - Rheumatoid arthritis: alleviates inflammation and joint damage progression. - Ankylosing spondylitis: diminishes spinal stiffness and pain. - Acute pain: provides short‑term relief of moderate to severe pain.

Common and serious adverse reactions have been reported with meloxicam use.

Common Side Effects: - Nausea or dyspepsia: mild stomach upset. - Headache: occasional mild pain. - Dizziness: transient light‑headedness.

Serious or Rare Side Effects: - Gastrointestinal ulcer or bleeding: potentially life‑threatening. - Hepatic dysfunction: elevated liver enzymes or hepatitis. - Renal impairment: reduced kidney function or acute failure.

Before prescribing meloxicam, clinicians should consider several safety measures. - Assess renal function: check baseline kidney parameters and monitor periodically. - Evaluate hepatic status: perform liver function tests prior to treatment. - Review cardiovascular risk: avoid in patients with recent myocardial infarction or uncontrolled hypertension. - Monitor gastrointestinal health: use caution in those with ulcer disease or on anticoagulants. - Avoid use in late pregnancy: meloxicam is contraindicated in the third trimester. - Store at ambient temperature: keep tablets below 25 °C in the original container, protected from moisture.

Meloxicam may interact with other medicines, altering efficacy or safety.

Major Interactions (Avoid): - Anticoagulants (e.g., warfarin): increased bleeding risk. - Other NSAIDs or COX‑2 inhibitors: heightened gastrointestinal toxicity. - ACE inhibitors or ARBs: may reduce renal function.

Moderate Interactions (Monitor Closely): - Diuretics: potential for reduced kidney perfusion. - Lithium: increased serum lithium levels. - Methotrexate: decreased clearance leading to toxicity.